Cu(ATSM) Cuts Alzheimer’s Amyloid-Beta 42% in Preclinical Study
Updated
Updated · Drug Target Review · Jun 15
Cu(ATSM) Cuts Alzheimer’s Amyloid-Beta 42% in Preclinical Study
3 articles · Updated · Drug Target Review · Jun 15
Summary
Monash University researchers found Cu(ATSM) cut toxic amyloid-beta proteins by 42% over 56 days in preclinical Alzheimer’s models, while improving spatial learning by nearly 44%.
The copper-based drug boosted P-glycoprotein clearance pumps at the blood-brain barrier by 24.1%, restoring a waste-removal system that normally weakens in Alzheimer’s disease.
Researchers said the results point to a treatment strategy aimed at neurovascular dysfunction rather than amyloid alone, linking blood-brain barrier repair to lower toxic protein buildup and better cognition.
Cu(ATSM) could move relatively quickly toward human trials because it has already undergone safety testing and clinical evaluation in other neurological conditions including Parkinson’s disease and ALS.
The team is still studying exactly how amyloid leaves the brain, including whether the drug also helps microglia break down plaques more effectively.
A copper compound shows promise in mice. Could it finally be the breakthrough Alzheimer's treatment for humans?
Is fixing the brain's 'drainage system' the real key to defeating Alzheimer's disease?
Cu(ATSM) Restores Brain Clearance in Alzheimer’s: Preclinical Breakthrough and Path to Human Trials
Overview
Alzheimer's disease is marked by the buildup of harmful amyloid-beta proteins in the brain. Normally, the brain uses a clearance system, including P-glycoprotein (P-gp) pumps at the blood-brain barrier, to remove these proteins. In Alzheimer's, these pumps lose effectiveness, leading to impaired removal and the accumulation of toxic proteins, which clogs the brain's waste disposal system. Recent research highlights Cu(ATSM) as a promising therapy that restores P-gp function, helping the brain clear amyloid-beta more effectively. This approach targets the root cause of protein buildup, offering hope for improved memory and brain health in Alzheimer's patients.